drugset / Trial / NCT00656851

Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome

NCT00656851

RandomizedParallel-groupOpen-labelDiagnostic

Summary

We hypothesize that the hearts of HIV+ people with The Metabolic Syndrome use and oxidize fats and sugars inappropriately, and that this may impair the heart's ability to pump blood. We hypothesize that exercise training or pioglitazone (Actos) will improve fat and sugar metabolism in the hearts of HIV+ people with The Metabolic Syndrome. This study will advance our understanding of cardiovascular disease in HIV+ people, and will test the efficacy of exercise training and pioglitazone for improving insulin resistance, heart metabolism and heart function in this at risk population.

Timeline

Start
2005-09
Primary completion
2009-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pioglitazone Small molecule 30 mg